AlphaCore Capital LLC Increases Position in AbbVie Inc. $ABBV

AlphaCore Capital LLC increased its position in shares of AbbVie Inc. (NYSE:ABBV) by 9.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 30,551 shares of the company’s stock after purchasing an additional 2,522 shares during the period. AlphaCore Capital LLC’s holdings in AbbVie were worth $7,074,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Diversified Trust Co grew its holdings in AbbVie by 23.6% during the 3rd quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock valued at $13,215,000 after buying an additional 10,891 shares in the last quarter. Permanent Capital Management LP bought a new stake in AbbVie in the 3rd quarter worth approximately $720,000. Railway Pension Investments Ltd raised its holdings in shares of AbbVie by 33.0% during the 3rd quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock worth $197,723,000 after acquiring an additional 211,800 shares in the last quarter. World Investment Advisors boosted its position in shares of AbbVie by 9.4% during the 3rd quarter. World Investment Advisors now owns 113,925 shares of the company’s stock valued at $26,378,000 after acquiring an additional 9,811 shares during the last quarter. Finally, Charles Schwab Trust Co boosted its position in shares of AbbVie by 93.4% during the 3rd quarter. Charles Schwab Trust Co now owns 32,105 shares of the company’s stock valued at $7,434,000 after acquiring an additional 15,502 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on ABBV shares. DZ Bank downgraded shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price target on the stock. in a research note on Tuesday, November 4th. Piper Sandler boosted their target price on shares of AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Citigroup decreased their target price on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 27th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. Finally, JPMorgan Chase & Co. boosted their price objective on AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Monday, November 3rd. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and a consensus price target of $253.15.

AbbVie Trading Down 0.6%

Shares of NYSE:ABBV opened at $227.01 on Thursday. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The company has a market capitalization of $401.38 billion, a price-to-earnings ratio of 96.19, a PEG ratio of 0.79 and a beta of 0.35. The firm’s 50-day moving average is $224.22 and its 200 day moving average is $222.70.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.65 by $0.06. The business had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same quarter last year, the firm earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, equities analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.0%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio is 293.22%.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie announced a $380 million investment to build two new API (active pharmaceutical ingredient) manufacturing facilities at its North Chicago campus — a multi‑year project expected to boost U.S. supply security, support production for obesity and other franchises, and create several hundred jobs (facilities targeted to be operational by 2029). AbbVie to build 2 API plants in Illinois
• Positive Sentiment: The FDA approved the VENCLEXTA (venetoclax) + acalabrutinib combination for first‑line treatment of CLL — the first all‑oral, fixed‑duration regimen for previously untreated patients, which should expand market opportunity and support oncology revenue growth. FDA Approves AbbVie (ABBV) VENCLEXTA and Acalabrutinib Combination for First-Line CLL
• Positive Sentiment: Barclays initiated coverage with an Overweight rating and a $275 price target, citing upside from operating leverage and under‑appreciated growth potential — a note that can improve sentiment among institutional investors. Barclays Initiates AbbVie (ABBV) with Overweight Rating on Growth Potential
• Neutral Sentiment: AbbVie completed a real‑world study of Vraylar in Bipolar I disorder — supportive real‑world evidence can aid uptake, but the near‑term revenue impact is limited. AbbVie’s Real‑World Vraylar Study in Bipolar I Disorder Reaches Completion
• Neutral Sentiment: AbbVie will present at the TD Cowen Health Care Conference on March 3 — a routine investor event that could provide incremental disclosure but not guaranteed news. AbbVie to Present at the TD Cowen 46th Annual Health Care Conference
• Neutral Sentiment: Multiple retail and dividend‑oriented writeups are highlighting AbbVie’s high yield and growing payout — this supports income‑investor interest but is unlikely to move the stock materially on its own. This High‑Yield Pharma Beast AbbVie Could Turn Dividends Into Life‑Changing Income
• Negative Sentiment: Analysts and research notes flag execution risk and intensifying competition across parts of AbbVie’s pipeline and immunology portfolio — these concerns are constraining upside in some models and tempering investor enthusiasm. How Pipeline Shifts And Competition Are Reshaping The AbbVie (ABBV) Investment Narrative
• Negative Sentiment: Valuation and momentum considerations (ABBV trades with a high P/E and recently near its 52‑week range) plus below‑average intraday volume can prompt profit‑taking even when company news is constructive.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.